Abstract:Objective: To investigate the mutation of the KRAS/NRAS/BRAF/PIK3CA gene and its relationship with clinicopathological features in colorectal cancer (CRC). Methods: The surgical resection specimens of 91 patients with primary CRC from 2012 to 2016 in Shanghai Fifth People's Hospital affiliated with Fudan University were collected for retrospective analysis. Detecting mutations in the KRAS/NRAS/BRAF/PIK3CA genes were confirmed by an amplification-refractory mutation system (ARMS). Immunohistochemistry (IHC) was conducted to confirm the expression of KRAS, NRAS, BRAF, and PIK3CA proteins.Results: Among 91 CRC patients, the mutation rates of the KRAS, NRAS, BRAF, and PIK3CA genes were 40.7% (37/91), 4.4% (4/91), 3.3% (3/91) and 2.2% (2/91), respectively. The KRAS/PIK3CA double mutation rate was 2.2% (2/91), and the KRAS/NRAS double mutation rate was 1.1% (1/91). The mutation rate of the BRAF gene in poorly differentiated CRC patients was significantly higher than that in moderately to well-differentiated patients (P < 0.05). PIK3CA gene mutation was significantly different between primary tumour sites (P < 0.05). The mutation rate of the KRNS/NRAS/BRAF/PIK3CA genes in patients with lymph node metastasis (78.3%, 18/23) was significantly higher than that in patients without lymph node metastasis (45.6%, 31/68) (P < 0.05). No significant differences in immunohistochemical expression between KRAS-, NRAS-, BRAF-, and PIK3CA-mutant patients and nonmutated patients were confirmed (P>0.05). Conclusions: KRAS mutation is the most common mutated gene in CRC patients. PIK3CA mutation is often accompanied by KRAS mutation, and EGFR treatment resistance in KRAS wild-type patients may be caused by PIK3CA gene mutation. Simultaneous detection of KRAS/NRAS/BRAF/PIK3CA gene mutations helps to develop the most accurate treatment for CRC patients. KRAS/NRAS/BRAF/PIK3CA gene mutations were associated with several clinicopathological features in this group of CRC patients, but more cases need to be confirmed by further studies. Gene mutations in CRC patients are best detected by DNA sequencing or ARMS methods.Funding Information: This work was supported by the High-level Professional Physician Training Program of Minhang District, Shanghai City (No. 2020MZYS10).Declaration of Interests: None.Ethics Approval Statement: The study was approved by the Ethical Committee of Shanghai Fifth People's Hospital, Fudan University (No. 2021071). Patients did not need to give informed consent because anonymous data were used in the analysis, which were obtained after each patient's written consent to treatment.

KRAS and BRAF genetic alterations in lung cancer: A case - control study

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

Kirsten rat sarcoma virus protein overexpression in adenocarcinoma lung: Association with clinicopathological and histomorphological features

Analysis Of Common Somatic Mutations In Colorectal Carcinoma And Associated Dysregulated Pathwaysarts

Frequency of KRAS and BRAF mutations in colorectal carcinoma and their association with clinical-pathological characteristics in a tertiary hospital in Kenya

BRAF mutations and the association of V600E with CD133 and CDX2 expression in a Pakistani colorectal carcinoma cohort

Abstract B009: Analysis of the KRAS mutation spectrum in Black/African American and White/European lung adenocarcinoma patients, and its association with patient survival

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

KRAS, NRAS and BRAF Mutational Profile of Colorectal Cancer in a Series of Moroccan Patients

The Factors Associated With Mutant Epidermal Growth Factor Receptor Positivity in Patients With Lung Cancer: A Study From a Tertiary Care Center in Pakistan

Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma

The Prevalence and Prognostic Significance of KRAS Mutation Subtypes in Lung Adenocarcinomas from Chinese Populations

KRAS as a Prognostic and Predictive Marker in Metastatic Non-Small Cell Lung Carcinoma: A Systematic Review

The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma

A Study on the Relationship Between KRAS, NRAS, BRAF and PIK3CA Gene Mutations and Clinicopathological Features in Patients with Colorectal Cancer

High Probability of Lynch Syndrome Among Colorectal Cancer Patients Is Associated With Higher Occurrence of KRAS and PIK3CA Mutations

Epidemiological and clinical characteristics of lung cancer in Saudi Arabia: a retrospective study in single oncology center

Molecular analysis of genetic mutations in non-small cell lung cancer in Morocco

Molecular characterization of lung carcinomas: A study on diagnostic, predictive, and prognostic markers using immunohistochemical analysis at a Tertiary Care Center in Uttarakhand, India

Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients.

Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma